Buscar
Barinthus Biotherapeutics PLC
BRNSAñadir a la lista de seguimiento
0.558USD
+0.007+1.29%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
22.79MCap. mercado
PérdidaP/E TTM
Más Datos de Barinthus Biotherapeutics PLC Compañía
Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company focused on developing immunotherapeutic candidates for treating autoimmune and inflammatory diseases. The Company’s pipeline, built around platform technologies; viral vector-based, consists of ChAdOx and MVA, and synthetic, consisting of SNAP-Tolerance Immunotherapy (SNAP-TI). These platforms help to develop antigen-specific immunotherapeutic candidates designed to optimize the disease fighting capabilities of T cells. It is focused on developing two product candidates that harness its viral vector and synthetic platform technologies. These include VTP-300, a Phase II immunotherapeutic candidate designed as a potential component of a functional cure for chronic hepatitis B virus infection utilizing ChAdOx/MVA, and VTP-1000, its autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease. The Company's pipeline also includes VTP-850, VTP-500 and VTP-400.
Información de Barinthus Biotherapeutics PLC
Símbolo de cotizaciónBRNS
Nombre de la empresaBarinthus Biotherapeutics PLC
Fecha de salida a bolsaApr 30, 2021
Director ejecutivoEnright (William J)
Número de empleados105
Tipo de seguridadDepository Receipt
Fin del año fiscalApr 30
DirecciónUnit 6-10, Zeus Building, Rutherford Avenue
CiudadDIDCOT
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited Kingdom
Código postalOX11 0DF
Teléfono441865818808
Sitio Webhttps://www.barinthusbio.com/
Símbolo de cotizaciónBRNS
Fecha de salida a bolsaApr 30, 2021
Director ejecutivoEnright (William J)
Ejecutivos de Barinthus Biotherapeutics PLC
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Geoffrey Lynn
Dr. Geoffrey Lynn
Chief Scientific Officer
Chief Scientific Officer
640.64K
--
Mr. Robin Wright
Mr. Robin Wright
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
48.26K
--
Dr. Pierre A. Morgon, Pharm.D.
Dr. Pierre A. Morgon, Pharm.D.
Non-Executive Independent Director
Non-Executive Independent Director
10.51K
--
Dr. Anne M. Phillips, M.D.
Dr. Anne M. Phillips, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
3.00K
--
Mr. William J. (Bill) Enright
Mr. William J. (Bill) Enright
Chief Executive Officer, Principal Financial Officer, Director
Chief Executive Officer, Principal Financial Officer, Director
--
--
Dr. Alex Hammacher
Dr. Alex Hammacher
Non-Executive Director
Non-Executive Director
--
--
Ms. Karen T. Dawes
Ms. Karen T. Dawes
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Joseph C. Scheeren
Dr. Joseph C. Scheeren
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Leon Hooftman, M.D.
Dr. Leon Hooftman, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Geoffrey Lynn
Dr. Geoffrey Lynn
Chief Scientific Officer
Chief Scientific Officer
640.64K
--
Mr. Robin Wright
Mr. Robin Wright
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
48.26K
--
Dr. Pierre A. Morgon, Pharm.D.
Dr. Pierre A. Morgon, Pharm.D.
Non-Executive Independent Director
Non-Executive Independent Director
10.51K
--
Dr. Anne M. Phillips, M.D.
Dr. Anne M. Phillips, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
3.00K
--
Mr. William J. (Bill) Enright
Mr. William J. (Bill) Enright
Chief Executive Officer, Principal Financial Officer, Director
Chief Executive Officer, Principal Financial Officer, Director
--
--
Dr. Alex Hammacher
Dr. Alex Hammacher
Non-Executive Director
Non-Executive Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Barinthus Biotherapeutics PLC?
Los cinco principales accionistas de Barinthus Biotherapeutics PLC son: Dr. Geoffrey Lynn
¿Cuántas instituciones poseen acciones de Barinthus Biotherapeutics PLC (BRNS)?
A fecha de 2026Q1, 32 instituciones poseen acciones de Barinthus Biotherapeutics PLC, con un valor de mercado combinado de aproximadamente 16.70M, lo que representa el 40.87% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -1943125.00.